Novozymes and Chr. Hansen are merging, aiming to provide “efficient, scalable, and sustainable biosolutions,” they announced. Uniting and optimizing the innovation platforms of both companies will bring together approximately 2,000 employees globally.
Novozymes delivers 10% organic sales growth and an EBIT margin of 26% in the first half of the year, despite the volatile market environment. The company announces it adjusted its full-year organic sales outlook from 4-8% to now 6-8%.